This inventor holds 2 USPTO granted patents and 1 published patent application. Top assignees: Harvard College, The General Hospital Corporation. Active years: 2024-2026.
Company Filing History:
2 out of 3,069 
2 out of 3,068 
Years Active: 2024-2026
Title: Killian S Hanlon: Innovator in Gene Therapy
Introduction
Killian S Hanlon is a notable inventor based in Cambridge, MA (US). He has made significant contributions to the field of gene therapy, particularly in addressing hereditary conditions such as hearing and vision loss.
Latest Patents
Hanlon holds a patent for a recombinant adeno-associated virus encoding clarin-1 and its uses. This patent focuses on compositions and methods for treating hereditary hearing loss and/or vision loss, specifically related to Usher syndrome, Type 3A. The invention includes a recombinant adeno-associated virus that comprises an AAV-S capsid protein and an isolated nucleic acid containing a transgene for expressing a clarin-1 protein. The methods outlined in the patent provide innovative approaches to treating these hereditary conditions.
Career Highlights
Throughout his career, Hanlon has worked with prestigious institutions such as Harvard College and The General Hospital Corporation. His work has been instrumental in advancing research in gene therapy and its applications in treating genetic disorders.
Collaborations
Some of his notable coworkers include Maryna V Ivanchenko and David P Corey. Their collaborative efforts have contributed to the development of groundbreaking research in the field.
Conclusion
Killian S Hanlon's work in gene therapy exemplifies the impact of innovative research on hereditary conditions. His contributions continue to pave the way for advancements in medical treatments.